INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $88,140 | -19.4% | 1,692,080 | -2.0% | 0.89% | -14.6% |
| Q2 2023 | $109,372 | +15.2% | 1,727,287 | -1.5% | 1.04% | +12.9% |
| Q1 2023 | $94,929 | +23.7% | 1,753,067 | +20.9% | 0.92% | +18.1% |
| Q4 2022 | $76,754 | -99.9% | 1,450,382 | -1.1% | 0.78% | +3.3% |
| Q3 2022 | $68,205,000 | +104.7% | 1,465,835 | +151.2% | 0.75% | +109.7% |
| Q2 2022 | $33,312,000 | -0.9% | 583,593 | +6.2% | 0.36% | +19.7% |
| Q1 2022 | $33,613,000 | +72.0% | 549,327 | +47.1% | 0.30% | +84.0% |
| Q4 2021 | $19,539,000 | – | 373,320 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |